Readability user testing is requested in EAEU October 15, 2020

Readability user testing is requested in EAEU

Does your company know that User Testing of Patient Information Leaflet (PIL testing/ Readability user testing (RUT)) of medicines is requested in EAEU region according to decision of the Eurasian Economic Commission (EEC) No. 88.?

To conduct PIL testing, you should:

  • be familiar with the EAEU rules
  • have appropriate experience in local markets
  • be able to perform testing in EAEU acceptable language.

Inpharmatis is an international consulting company with more than 15 years’ experience in EAEU, CIS and EU markets in the field of regulatory services for pharmaceutical companies.

We are delighted to propose PIL testing in EAEU performed by Inpharmatis - leading provider with great practical experience and expertise of PIL testing in EAEU region.

Inpharmatis has been involved with readability testing since the beginning of the EU requirement in 2005.

We offer:

  • PIL EAEU expertise according to EAEU requirements (also based on previous successful EU experience)
  • Guaranteed Acceptance Across the EAEU requirements
  • Bridging studies for readability user testing
  • Highly qualified multilanguage User Testing Project team located in each country of EAEU
  • PIL GAP analysis versus requirements of EEC Decision No. 88.
  • EU or National PIL reformatting according to EAEU requirements
  • PIL and SmPC translation to most EAEU languages
  • Quick implementation of the project
  • Conduct the validated Readability User Testing in EAEU acceptable languages
  • Validated quality procedures
  • Flexible price

Our approval rates are 100% - leaving aside projects where clients have ignored our initial advice regarding leaflet changes.

If you want to conduct PIL testing and find out further information, please contact us info@inpharmatis.com.

New requirements for medicine registration in the EU will improve global data exchange between pharmaceutical companies and regulators

June 14, 2021

Новые требования к подаче сведений при регистрации лекарственных средств в Евросоюзе улучшат глобальный обмен данными между фармкомпаниями и регуляторами

June 10, 2021

Inpharmatis принял участие в работе ПМЭФ-2021

June 04, 2021

Ольга Звонарева возглавит в Inpharmatis направление Regulatory Affairs в России и странах СНГ

May 31, 2021

Inpharmatis appoints new RA Director in Russia & CIS

May 31, 2021

Приведение досье в соответствие с правилами ЕАЭС

May 27, 2021

Bringing the dossier in accordance with the rules of the EAEU

May 27, 2021

Inpharmatis и «АКАДЕМФАРМ» обсудили в Минске перспективы сотрудничества

May 21, 2021

Inpharmatis and “ACADEMPHARM” discussed in Minsk cooperation opportunities

May 21, 2021

Participation in IPhEB Russia 2021

April 19, 2021